BariaTek Medical Receives € 1.5M DeepTech Non-dilutive Financing From Bpifrance

Obesity and diabetes are debilitating conditions affecting more than 1 billion patients worldwide; they are the most costly chronic conditions to healthcare systems surpassing cardiovascular diseases and cancer and their prevalence is increasing. Obesity and diabetes are pandemics increasingly affecting patients in every corner of the globe.

BariaTek Medical, a privately held medical device company dedicated to the development of minimally invasive endoscopically delivered solutions to treat obesity and diabetes, founded by Truffle Capital, announced it has secured a non-dilutive DeepTech financing of € 1.5 million from Bpifrance, under the “France 2030” plan, to accelerate the company's development towards its imminent human feasibility clinical trials.

Read the press release